![](\"https:\/\/mms.businesswire.com\/media\/20260624633455\/en\/2836643\/4\/Antares_ID_Htx_C.jpg\")
<\/a><\/a>\nUnder the terms of the agreement, Antares will receive a $105 million upfront payment and is eligible to receive up to $1.8 billion in additional payments across programs, inclusive of option exercise, development, regulatory, and commercial milestones, as well as tiered royalties on global net sales up to the low double-digit range. Antares will lead all research and apply its proprietary discovery engine to a limited number of historically undruggable targets until option exercise. In parallel, Antares will continue to advance its wholly owned and partnered portfolio of precision medicines for cancer and other serious diseases.<\/p>
\n\u201cFrom the outset, our goal has been to build a discovery engine that systematically unlocks high-value, challenging targets and delivers first-in-class precision medicines,\u201d said Adam Friedman, M.D., Ph.D., Chief Executive Officer of Antares. \u201cThis collaboration lets us scale that engine alongside Novartis\u2019 world-class development capabilities and global reach, so we can translate our science into transformative therapies for patients faster than either of us could alone. It builds on the work of a team that has consistently produced highly selective medicines against some of the hardest targets in drug discovery.\u201d<\/p>
\nThe collaboration pairs Antares\u2019 covalent drug discovery expertise \u2013 proprietary screening libraries, chemical proteomics capabilities, structure-driven computational chemistry and a machine-learning suite purpose-built for compelling first-in-class targets \u2013 with Novartis\u2019 world-class R&D and global resources.<\/p>
\n\u201cNovartis is committed to advancing innovative approaches to cancer drug discovery and expanding the boundaries of what's possible in oncology treatment,\u201d said Fiona Marshall, President of Biomedical Research at Novartis. \u201cMany of the most compelling targets today in oncology have historically been considered undruggable. We believe this collaboration has the potential to unlock a new wave of targeted therapies and bring meaningful advances to patients.\u201d<\/p>
\nAbout Antares Therapeutics<\/b><\/p>
\nAntares Therapeutics is a biotechnology company developing transformational, first-in-class precision medicines with a focus on validated, undruggable targets in cancer and other serious diseases with large unmet need. Antares\u2019 lead precision oncology program is expected to enter the clinic in 2026, with multiple additional programs in preclinical development. To learn more, visit www.antaresrx.com<\/a> and follow us on LinkedIn<\/a>.<\/p> \nMedia Contact:<\/b> \u2013 Multi-target collaboration will leverage Antares\u2019 proprietary discovery engine to generate highly selective small molecule medicines against historically undruggable oncology targets \u2013
\n\u2013 Antares to receive $105M upfront and is eligible for up to $1….<\/p>\n","protected":false},"author":2,"featured_media":0,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[1],"tags":[],"class_list":["post-25482","post","type-post","status-publish","format-standard","hentry","category-infos-businesswire"],"_links":{"self":[{"href":"https:\/\/stocks-future.com\/index.php?rest_route=\/wp\/v2\/posts\/25482","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/stocks-future.com\/index.php?rest_route=\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/stocks-future.com\/index.php?rest_route=\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/stocks-future.com\/index.php?rest_route=\/wp\/v2\/users\/2"}],"replies":[{"embeddable":true,"href":"https:\/\/stocks-future.com\/index.php?rest_route=%2Fwp%2Fv2%2Fcomments&post=25482"}],"version-history":[{"count":1,"href":"https:\/\/stocks-future.com\/index.php?rest_route=\/wp\/v2\/posts\/25482\/revisions"}],"predecessor-version":[{"id":25483,"href":"https:\/\/stocks-future.com\/index.php?rest_route=\/wp\/v2\/posts\/25482\/revisions\/25483"}],"wp:attachment":[{"href":"https:\/\/stocks-future.com\/index.php?rest_route=%2Fwp%2Fv2%2Fmedia&parent=25482"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/stocks-future.com\/index.php?rest_route=%2Fwp%2Fv2%2Fcategories&post=25482"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/stocks-future.com\/index.php?rest_route=%2Fwp%2Fv2%2Ftags&post=25482"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}